Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, 214062 Wuxi, People's Republic of China; Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122 Wuxi, People's Republic of China; Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, 214122 Wuxi, People's Republic of China.
Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, 214062 Wuxi, People's Republic of China; Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, 214122 Wuxi, People's Republic of China.
J Control Release. 2023 Dec;364:672-686. doi: 10.1016/j.jconrel.2023.11.013. Epub 2023 Nov 17.
Small extracellular vesicles (sEVs) have shown excellent prospects as drug delivery systems for cancer therapy. However, the inherent non-targeting and short blood circulation characteristics severely restrict their practical applications as a delivery system. In addition, post-encapsulating drugs into sEVs also remains challenging. Here, we constructed an engineered cell line that secreted multifunctional sEVs (termed NBsEV204) with 7D12 (an anti-EGFR nanobody) and hCD47 decorations on their surface, as well as high levels of miR-204-5p encapsulation. NBsEV204 exhibited extended blood circulation and improved macrophage-mediated phagocytosis of tumor cells by blocking CD47 signaling. Importantly, NBsEV204 specifically targeted EGFR tumor cells and showed robust tumor-suppressive effects both in vitro and in vivo. Overall, this study provides a convenient and feasible method to produce off-the-shelf anticancer sEV nanomedicine, which exhibits tremendous potential for clinical translation.
小细胞外囊泡(sEVs)作为癌症治疗的药物递送系统具有广阔的应用前景。然而,其固有的非靶向性和短血液循环特性严重限制了其作为递送系统的实际应用。此外,将封装后的药物载入 sEVs 也仍然具有挑战性。在这里,我们构建了一个工程细胞系,该细胞系分泌多功能 sEVs(称为 NBSEV204),其表面具有 7D12(一种抗 EGFR 纳米抗体)和 hCD47 修饰,以及高水平的 miR-204-5p 封装。NBSEV204 表现出延长的血液循环和改善巨噬细胞介导的肿瘤细胞吞噬作用,通过阻断 CD47 信号。重要的是,NBSEV204 特异性靶向 EGFR 肿瘤细胞,并在体外和体内均表现出强大的肿瘤抑制作用。总的来说,本研究提供了一种方便可行的方法来生产现成的抗癌 sEV 纳米药物,具有巨大的临床转化潜力。